Clinical trials: Viral Respiratory Infection
Respiratory Syncytial Virus
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age.
- Trial name
- NCT06060457
- Testing
- mRNA-1345, Fluzone HD
- Where
- 34 sites in United States
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Immunization; Infection, Pregnancy Related
VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination
COVID-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. Pregnant people with COVID-19 have a higher rate of ICU admission and intubation than those who are not…
- Conditions
- Immunization; Infection, Pregnancy Related, COVID-19
- Trial name
- NCT05570630
- Testing
- VAX-MOM COVID-19 Intervention, Standard of Care
- Where
- United States
- Volunteers
- 6,911 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Primary Objective: To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00831311
- Testing
- DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- Where
- Argentina
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Sars-CoV-2 Infection, COVID-19
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
SARS-CoV-2 rapid antigen over the counter usability study.
- Trial name
- NCT05584189
- Testing
- Rapid SARS-CoV-2 Antigen Test
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
- Trial name
- HITCH (NCT04397718)
- Testing
- Degarelix, Saline
- Where
- 14 sites in United States
- Volunteers
- 96 people
- Sponsor
- VA Office of Research and Development
SARS-CoV2 Infection, COVID-19
BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)
This is a study of the BinaxNOW Covid-19 Ag Card as a method to rapidly identify SARS-CoV-2 infection in asymptomatic children, teachers, and other school staff for exclusion.
- Trial name
- NCT05087524
- Testing
- BinaxNOW Ag Card
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
COVID 19
Inhaled Ciclesonide for Outpatients With COVID19
The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent.
- Trial name
- CONTAIN (NCT04435795)
- Testing
- Ciclesonide, Ciclesonide nasal
- Where
- 3 sites in Canada
- Volunteers
- 215 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19
- Trial name
- TREATNOW (NCT04372628)
- Testing
- Lopinavir/Ritonavir 400 mg/100 mg
- Where
- 6 sites in United States
- Volunteers
- 452 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
- Trial name
- NCT05817045
- Testing
- RD-X19
- Where
- 48 sites in United States
- Volunteers
- 330 people
- Sponsor
- EmitBio Inc.
Hepatitis B, Chronic Hepatitis B Atypical
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection
- Trial name
- NCT02981602
- Testing
- IONIS-HBVRx
- Where
- 7 sites in Hong Kong, South Korea
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
COVID-19 Infection
"CHANGE COVID-19 Severity"
We are conducting an investigator-initiated, single center, blinded, placebo-controlled, randomized clinical trial evaluating magnesium citrate combined with a probiotic for the treatment of adults hospitalized with COVID-19.
- Trial name
- CHANGE (NCT04941703)
- Testing
- Magnesium Citrate plus probiotic
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University Medical Center
COVID-19, Cancer
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer.
- Trial name
- NCT04381988
- Testing
- Hydroxychloroquine, Radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcopenia
Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.
Sarcopenia is the major health concern and common consequence of COVID-19 in the aging population. Moreover, this clinical condition has not been considered in usual physical rehabilitation practice, and its optimal protein…
- Trial name
- NCT05224453
- Testing
- Physical training and high protein diet, Physical training and low protein diet
- Where
- Saudi Arabia
- Volunteers
- 76 people
- Sponsor
- Prince Sattam Bin Abdulaziz University
Anxiety, COVID-19 Pandemic
SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations During COVID-19
The goal of this clinical trial is to evaluate the SMILE app, a Digital Health Platform (DHP), that will deliver a mindfulness intervention, designed to mitigate COVID-19 related stress.
- Trial name
- SMILE (NCT06242080)
- Testing
- Mindfulness
- Where
- United States
- Volunteers
- 398 people
- Sponsor
- University of North Carolina, Chapel Hill
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
COVID-19 Testing Behaviors
Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing
In this Phase III study, the investigators will build off of the Phase II embedded study with some adjustments to the design to address new research priorities that examine an intervention that is network informed and delivered…
- Trial name
- NCT07074171
- Testing
- Text message-based education intervention, Historical Control
- Where
- 3 sites in United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.